[Featured Stock] Prostemix Expected to Have Hair Loss Treatment More Effective Than Minoxidil... Focused on Hair Loss Pledge Issues

[Asia Economy Reporter Hyungsoo Park] Prostemics' stock price is on the rise. It appears to be influenced by the surge in related stocks following Lee Jae-myung, the Democratic Party presidential candidate, mentioning the application of health insurance coverage for hair loss treatment drugs.

As of 9:49 AM on the 6th, Prostemics is trading at 3,135 KRW, up 10.19% compared to the previous trading day.

On the 4th, candidate Lee Jae-myung announced as part of his small but certain happiness (So-hwak-haeng) pledge that he is considering applying health insurance coverage to hair loss treatment drugs. On Facebook, he wrote, "For 毛 (mo)! For me!" and posted a video in which he personally appeared saying, "Are you voting for Lee Jae-myung? Lee Jae-myung is about planting."

Candidate Ahn Cheol-soo also shared on his Facebook a pledge to lower the price of generic hair loss drugs. If health insurance is applied, the burden on patients will decrease, potentially leading to rapid growth in the hair loss-related market.

With one in five citizens reportedly concerned about hair loss, the younger generation is responding to candidate Lee Jae-myung's pledge. Hair loss-related pledges seem to be becoming a central issue in the presidential election phase.

Prostemics is developing bio new drugs (PSI-101) and chemically synthesized new drugs (PSI-65X) as hair loss treatments. They are researching mechanisms of action such as promoting regeneration of hair cells (dermal papilla cells), increasing hair growth factors, and activating hair growth-related signaling pathways. The treatment uses exosomes and exosomal microRNA derived from human adipose stem cells.

Last year, they obtained a patent for a pharmaceutical composition for preventing hair loss and promoting hair growth. The patent concerns various uses of compositions containing plant-derived extracellular vesicles.

Regarding the related patent, Prostemics stated, "Plant-derived extracellular vesicles have higher efficacy in preventing hair loss or promoting hair growth compared to the positive control minoxidil, including promoting proliferation of dermal papilla cells, increasing hair growth-related genes, and enhancing hair growth in human follicle tissue."

They added, "We plan to utilize the patent in cosmetic development," and "We expect it to be applied to the development of hair loss treatments using the plant-derived extracellular vesicles."